Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 12/20 | 0.51 |
| ▸ | SLC2A3 | P11169 | 12/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.47 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.41 |
| ▸ | CLK2 | P49760 | 1/20 | 0.41 |
| ▸ | BLK | P51451 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | STK3 | Q13188 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27248907 | 0.92 | HDAC3 (0.51) | SLC2A1SLC2A3ROCK2ROCK1HDAC3 | |
| SCHEMBL27248797 | 0.91 | SLC2A1 (0.53) | SLC2A1SLC2A3ROCK2ROCK1PRKCI | |
| SCHEMBL27248662 | 0.86 | SLC2A1 (0.52) | SLC2A1SLC2A3ROCK2ROCK1HDAC3 | |
| SCHEMBL27248864 | 0.85 | SLC2A1 (0.49) | SLC2A1SLC2A3ROCK2ROCK1CLK2 | |
| SCHEMBL27249057 | 0.84 | SLC2A1 (0.48) | SLC2A1SLC2A3ROCK2ROCK1CLK2 | |
| SCHEMBL27248903 | 0.84 | SLC2A3 (0.51) | SLC2A1SLC2A3PRKCIHDAC3HDAC4 | |
| SCHEMBL27248854 | 0.83 | SLC2A1 (0.48) | SLC2A1SLC2A3ROCK2ROCK1CLK2 | |
| SCHEMBL27248607 | 0.83 | HDAC3 (0.53) | SLC2A1SLC2A3ROCK2HDAC3HDAC4 | |
| SCHEMBL27248852 | 0.82 | ROCK2 (0.50) | SLC2A1SLC2A3ROCK2ROCK1CLK2 | |
| SCHEMBL27248493 | 0.82 | SLC2A1 (0.56) | SLC2A1SLC2A3ROCK2ROCK1CLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360085-A1 | Glucose Uptake Inhibitors | KADMON CORPORATION, LLC (US) | 2024-10-31 | — | — | US | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-20220363648-A1 | Glucose Uptake Inhibitors | KADMON CORPORATION, LLC | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030857-B2 | Glucose uptake inhibitors | SLC2A1, SLC2A4, SLC2A2 | SLC2A1 1/4885SLC2A3 4/4885ROCK2 3701/4885 |
| US-20220363648-A1 | Glucose Uptake Inhibitors | SLC2A1, SLC2A4, SLC2A2 | SLC2A1 1/4885SLC2A3 4/4885ROCK2 3701/4885 |
| US-20240360085-A1 | Glucose Uptake Inhibitors | SLC2A3, SLC2A1, SLC2A4 | SLC2A1 2/4885SLC2A3 1/4885ROCK2 3707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.